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1.1. Neuroendocrine tumors 
Neuroendocrine tumors (NETs) are neoplastic lesions originating from progenitor 
cells that resemble both neurons and endocrine cells. They share common 
structural features (specific antigens) and functional characteristics (secretory 
vesicles) with both cell types. Due to their ability to produce hormones and 
neurotransmitters, these cells are referred to as neuroendocrine cells. Since 
neuroendocrine tissue is organized in islets within endocrine glands or dispersed 
as diffuse endocrine system throughout the whole body, NETs can arise from 
various organs (Figure 1). 
 
 
Figure 1. Localizations of NETs in the human body. Modified according to ref. [1]. 
 
Depending on their embryological development, NETs are subdivided into 
foregut, midgut, hindgut and extraintestinal derivates. Most commonly they 
emerge from the gastrointestinal system followed by the bronchopulmonary 
Introduction 
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system.[2] Yet, some have also been noticed in the hepatobiliary and urogenital 
system and may arise from (extra) adrenal paraganglia, nerve plexuses, the 
breast and the skin. Based on the actual organ site, there is a large variety of 
clinical progression and outcome. While sporadic NETs of specific locations 
rather develop at an older age, NETs of other sites occur in younger people, 
particularly those associated with inherited syndromes like neurofibromatosis 
type 1 (NF1), multiple endocrine neoplasia type 1 (MEN1), von Hippel-Lindau 
disease (VHL) or tuberous sclerosis (TSC1).[3] 
NETs are separated into two species dependent on their secretory activity: (1) 
functionally active tumors which release diverse hormones (polypeptides such as 
gastrin and biogenic amines like serotonin), neurotransmitters, mediators, growth 
factors and cytokines corresponding to their tissue of origin and (2) functionally 
inactive tumors. Although both groups produce and store secretory products, 
functionally active NETs are characterized by excessive hormone release. This, 
in turn, can lead to substance-specific symptoms, for example the Zollinger-
Ellison syndrome in case of gastrinoma. 
The US National Cancer Institute’s Surveillance, Epidemiology and End Results 
(SEER) study pointed out that with a rising incidence from 1.09/100,000 in the 
1970s to 5.25/100,000 in 2004 this comparatively rare tumor entity has grown 
remarkably in importance over the last decades. A significant part of the 
diagnosed NETs (20-50%, depending on tumor differentiation) presented 
contemporaneous distant metastases, which reduced the median survival from 
223 to 33 months in case of well to moderately and from 34 to 5 months in case 
of poorly differentiated NETs, respectively.[4] 
There have been many different nomenclature and classification attempts in 
order to define NETs but they were inconsistent regarding the tumor precursor 
cells.[5]  
Despite these heterogeneous tumors being largely grouped together as one 
entity, an early and precise detection of the tumor with its organ of origin, grade 
and stage are crucial for the prognosis and survival. In order to standardize the 
diagnosis and treatment conditions, the World Health Organization (WHO) has 
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set a histologically based grading and classification system in 2010. The grading 
criteria, however, vary among the different organs. Regarding invasiveness and 
capacity to spread, all NETs are potentially malignant tumors. Considering the 
extent of the primary tumor (T), lymph node metastases (N) and distant 
metastases (M), they are staged by the TNM classification system developed by 
the Union for International Cancer Control (UICC). The strongly variable 
prognostic value among this heterogeneous tumor entity and the need of a proper 
patient stratification resulted in the establishment of separate TNM classifications 
for different localizations. As largest subgroup, NETs of the 
gastroenteropancreatic system (GEP-NETs, including gastric, intestinal and 
pancreatic NETs) have been classified separately by the European 
Neuroendocrine Tumor Society (ENETS) prior to the UICC categorization. 
1.2. Neuroendocrine tumors of the small intestine 
1.2.1. Epidemiology 
NETs of the small intestine (SI-NETs) have their origin in the diffuse endocrine 
system of the duodenum, jejunum and most commonly of the ileum. With 28.5%, 
SI-NETs represent a major part of all gastrointestinal NETs.[2] Although in general 
they are rare, with an incidence of approximately 1/100,000 cases, there tumors 
are the most frequent malignant tumor of the small intestine with an increasing 
prevalence.[6] 
Not only have the improvements in classification and diagnostics given rise to the 
step-up in incidence. The influence of alimentary factors is being discussed as 
well.[4] The gender and race distribution varies among different countries. While 
the male-to-female ratio is fairly balanced in total, the African American ethnicity 
is more affected than other ethnic groups.[4,7] SI-NETs predominantly emerge in 
patients between 60 and 70 years and despite the majority occurring sporadically, 




Most frequently, SI-NETs evolve from enterochromaffin (EC) cells located in the 
basal mucosal epithelia disseminated throughout the intestinal system (Figure 2). 
Their function is to regulate the digestive activity by paracrine secretion of 
serotonin and bioactive mediators. Stored in secretory granules these hormones 
give EC cells a fine-grain appearance. Beyond that, there are more 
neuroendocrine cells of the small intestine, such as the enteroglucagon (L) cells 
which balance the blood sugar level, or neurotensin (N) cells adjusting acidity and 
motility. However, tumors of these origins are extremely rare. 
 
 
Figure 2. EC cells in the intestinal mucosa. EC cells (green) in the intestinal crypts store and release 
serotonin granules (dark blue). Modified according to ref. [10]. 
 
Analogous to the neuroendocrine cells of the gastrointestinal system that in total 
represent the largest endocrine organ, SI-NETs express nonspecific 
neuroendocrine biomarkers such as chromogranin A, synaptophysin and neuron-
specific enolase. In addition, they exhibit type-specific markers like somatostatin 
receptors (SSR) on their cell surface, or their synthesis products. With regard to 
their histological appearance, there are four potential growth patterns: (1) nodular 




As a subgroup of GEP-NETs, neuroendocrine neoplasms of the small intestine 
are graded by the WHO (2010) classification considering their differentiation and 
proliferation rate into low grade (G1: Ki-67 proliferation index ≤ 2%, < 2 mitoses 
/ 10 high power fields [HPF] with a size of 2 mm2 each), intermediate grade (G2: 
Ki-67 index 3-20%, 2 - 20 mitoses / 10 HPF) well differentiated neuroendocrine 
tumors and high grade (G3: Ki-67 index > 20%, > 20 mitoses / 10 HPF) poorly 
differentiated neuroendocrine carcinomas (Table 1).[12] 
 
Table 1. WHO classification and histopathological grading of NETs of the digestive system.  
Classification Grade Mitotic count 
(per 10 HPF) 
Ki-67 index 
NET G1 (low grade) <2 ≤2 % 
NET G2 (intermediate 
grade) 
2-20 3-20% 
NEC G3 (high grade) >20 >20% 
 
SI-NETs generally grow slowly (mostly graded G1/G2) and reach an average size 
of a few centimeters. The macroscopic appearance of an ileal NET is depicted in 
Figure 3. Two different histologic growth patterns of digestive NETs are 




Figure 3. Macroscopic appearance of an ileal NET. The tumor stands out as a whitish, fibrotic mass. 
Retrieved from: http://www.hpbsurgery.co.za/intestinal-tumours.php. Date accessed: 06/04/2017  
 
 
Figure 4. Histology of digestive NETs. H&E stainings. a) Trabecular / solid / gyriform patterns with b) minor 
cellular atypia are characteristic of G1 tumors. c) Consolidated trabecular structures with d) moderate atypia 




Once they expand from the tela submucosa to the tunica muscularis mucosae 
SI-NETs are likely to spread out lymph node or distant metastases, which is 
classified by the TNM system of neuroendocrine tumors of the small intestine 
(Table 2). According to the particular parameters for the extent of the primary 
tumor, lymph node and distant metastases, SI-NETs are grouped into different 
stages, as demonstrated in Table 3. 
 
Table 2. UICC TNM (7th edition) clinical classification of NETs of the small intestine. 
T  Primary tumor: add (m) for multiple tumors 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
T1 Tumor invades lamina propria or submucosa and is ≤ 1 cm in size 
T2 Tumor invades muscularis propria or is > 1 cm in size 
T3 
Jejunal or ileal tumor invades subserosa 
Ampullary or duodenal tumor invades pancreas or retroperitoneum 
T4 
Tumor perforates visceral peritoneum (serosa) or invades other organs or 
adjacent structures 
N  Regional lymph nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
M  Distant metastasis 
M0 No distant metastasis 
M1 Distant metastasis  
Introduction 
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Table 3. UICC stage grouping corresponding to TNM criteria of non-appendiceal gastrointestinal NETs. 
Stage  Corresponding TNM criteria 
Stage I T1 N0 M0 
Stage IIA T2 N0 M0 
Stage IIB T3 N0 M0 
Stage IIIA T4 N0 M0 
Stage IIIB Any T N1 M0 
Stage IV Any T Any N M1 
 
Since metastases are often considered a life-limiting factor, SI-NETs show a high 
potential for malignancy in contrast to the mostly benign NETs of the stomach 
and of the appendix.[14] 
1.2.3. Clinical appearance and diagnosis 
Unlike other types of NETs, SI-NETs are not part of congenital syndromes and 
therefore, do not show specific symptoms. Since most of them are small, slowly 
growing and functionally inactive, they tend to be diagnosed late, sometimes 
even coincidently during other examinations or surgery. 
Usually this tumor manifests very late with unspecific problems like pain, nausea 
and vomiting due to the bulk expansion. In contrast, serotonin as main secretory 
substance has various concealed effects on the environment of SI-NETs. It 
stimulates the proliferation of fibroblasts, endothelial cells and induces smooth 
muscle growth.[15] However, only in less than 10% of the patients and only in case 
of functional activity, excessive secretion of serotonin or mediators like kallikrein, 
tachykinins or prostaglandins can provoke a particular symptom complex 
denoted as carcinoid syndrome.[16] It not only includes local effects of 
inappropriate serotonin and growth factor release such as desmoplastic reaction, 
intestinal obstruction and ischemia but more importantly has a systemic impact. 
The most common systemic manifestations are flushing, diarrhea, abdominal 
pain, palpitations, endocardial fibrosis, valvular heart disease and heart failure 
(referred to as carcinoid heart disease CHD). Occasionally symptoms like 
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bronchial constriction and spasm, wheeze, teleangiectasia, arthritis and pellagra 
occur.[3] If enhanced by stress or medical procedures facilitating mediator release 
(such as intraoperative mechanical stimulation), carcinoid syndrome can devolve 
into a life-threatening crisis with signs of medical shock.[16]  
A common characteristic of SI-NETs is the extensive metastatic spread leading 
to lymph node metastases in 60% of the patients at the time of diagnosis and to 
metastases in general in more than 70% over the course of time, regularly gaining 
a multiple of the primary tumor’s size.[3,17] As the most affected organ by distant 
metastases, the liver becomes functionally restricted and fails to inactivate 
circulating vasoactive hormones and mediators. Insufficient metabolization 
explains why the few specific symptoms of SI-NETs mainly present in patients 
with advanced, metastatic SI-NETs.  
For diagnostic purposes, medical history and physical examination usually are 
not informative. Laboratory findings may detect an excess of secretory markers 
(serotonin, neurokinin A, neuropeptide K, substance P) and biomarkers for CHD 
(natriuretic peptides) in blood serum or urinary 5-hydroxyindoleacetic acid (5-
HIAA) as metabolic product of serotonin.[11,17]  
Over the last years, diagnostic imaging has become more and more important for 
identifying the tumor and metastases, choosing the right treatment, monitoring its 
response and for follow-ups. This is due to two factors: first, diagnostic radiology 
came up with a variety of highly specific visualization methods; second, the 
advance in image resolution has remarkably improved the detection rate of these 
mostly small tumors. Nevertheless, none of the available imaging techniques 
achieve to gather all required information at once, making multimodal imaging 
necessary. Giving a rough insight into the gastrointestinal tract and the possibility 
to navigate a subsequent biopsy if needed, transabdominal sonography is a good 
starting point for further investigations. Especially power Doppler sonography is 
used to visualize the vascularization of the tumor mass and, in appropriate cases, 
enteroscopy or endocapsule imaging provide a higher resolution image of the 
suspicious segment. Conventional (contrast-enhanced) computed tomography 
(CT), magnetic resonance imaging (MRI), 111In-Octreotide somatostatin receptor 
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scintigraphy (SSRS) and 68Ga positron emission tomography (PET) are likewise 
used for identifying SI-NETs and, once they have been diagnosed, for staging 
and determining the resectability.[17,18] Figure 5 illustrates a typical contrast-
enhanced CT of an ileal NET during the portal venous phase presenting a 
mesenteric node metastasis (a) and a hepatic metastasis (b). Figure 6 depicts a 
T1-weighted (a) and T2-weighted (b) MRI sequence of a hepatic NET metastasis. 
 
 
Figure 5. Contrast-enhanced CT of an ileal NET. Portal venous phase imaging. a) Primary tumor in a sagittal 




Figure 6. Axial MRI of a hepatic NET metastasis. a) T1-weighted, b) T2-weighted image of the metastatic 




Further functional imaging techniques aim to display particular features. For 
example the metabolism of glucose as indicator of a tumor’s mitotic rate can be 
detected by 18F-fluorodeoxyglucose (FDG) PET (generally low in SI-NETs), 
amine uptake and decarboxylation (characteristic for SI-NETs regardless of 
functional activity) can be verified by 18F-DOPA PET, and the identification of 
SSR can be visualized with 68Ga-DOTATOC (radiolabeled SSR ligand) PET/CT 
giving direction to the therapeutic setting.[18] 
1.2.4. Therapy and prognosis 
The overall outcome is extremely affected by tumor dissemination at the time of 
diagnosis that is usually significant because of late and nonspecific clinical 
manifestation and poor response to standard cancer therapy. This is exemplified 
by the median survival for localized small bowel NETs of 111 months decreasing 
to 105 months in case of regional node metastases and to 56 months in case of 
distant metastases.[4] 
Although limited by the extent of tumor spread and the patient’s comorbidities, 
radical surgical resection of primary tumor and metastases is the only way to cure 
the patient. Thus, surgery intending a R0 situation (no residual tumor mass) is 
considered first-line therapy. If the tumor is not completely resectable the patient 
can undergo a multidisciplinary treatment approach consisting of cytoreductive 
surgery, medication and interventional radiotherapy.  
Cytoreductive surgery aims to reduce bulk volume related symptoms. In addition, 
the response to subsequent treatment can be augmented by removing tumor and 
metastatic mass (by usually 70-90%) if possible.[19]  
The global aim of palliative medication is to decelerate tumor growth, decrease 
the symptoms of abundant hormones and in doing so improve the quality of life. 
Interferons such as Interferon-α are established as universal anti-tumor drugs 
because they stimulate the immune system and thereby support the endogenous 
control over tumor growth. Even though effective for SI-NETs, they are not 
tolerated by all patients because of multiple side effects.  Another essential 
therapeutic target for functionally active SI-NETs is somatostatin. This peptide 
hormone acts as inhibitory counterpart to most of the gastrointestinal hormones, 
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which pharmacologically can be taken advantage of. Somatostatin analogs 
(SSAs, binding to somatostatin receptors 1-5) such as Octreotid or Lanreotid 
have proven to be successful anti-proliferative substances with low side effects. 
Besides, SSAs are used as preoperative medication preventing the carcinoid 
crisis. 
Complementary to surgery and medication, radiotherapy is a palliative procedure 
widely used for the elimination of liver metastases. This can be achieved by 
locally ablative procedures like radiofrequency ablation (RFA), cryotherapy, 
transarterial (chemo)embolization (TAE / TACE) or radioembolization like 
selective internal radiation therapy (SIRT). Peptide-receptor radionuclide therapy 
(PPRT) with radiolabeled SSA (90Y-DOTATOC or 177Lu-DOTATATE) allows for a 
selective uptake of the β-emitter isotopes by SSR expressing tumor cells limiting 
the damage of surrounded tissue.[17]  
Since cytotoxic chemotherapy is most effective for highly proliferative cancer, it 
is an option for NECs, but not applicable for the slowly growing NETs due to their 
lack of response. 
Despite improved diagnostic methods and the mentioned treatment trials, the 5 
year survival rate of 60% has not changed over the last decades, which points to 
the necessity of innovative treatment options.[11] Following the first successful 
substances in diverse studies on individualized GEP-NET immunotherapy like 
Bevacizumab (monoclonal antibody inhibiting vascular endothelial growth factor 
VEGF), Sunitinib (multi-targeted tyrosine kinase inhibitor) and Everolimus 
(mammalian target of rapamycin mTOR inhibitor), inhibitory agents in tumorigenic 
signal pathways and cell environments are highly demanded.[11] Therefore, 
however, a greater understanding of the underlying genetics and protein 
expression has to be attained. 
1.2.5. Findings of recent studies 
Genetic instability such as chromosome and nucleotide rearrangements has 
proven to play an important role in carcinogenesis. Defects in DNA damage 
repair, chromatin remodeling and mitosis / apoptosis regulation are the most 
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prominent factors to misbalance cell growth and proliferation. The prognosis in 
general is associated with the amount of karyotypic variations.[20] 
Since the molecular etiology of NETs is largely still unknown, recent research has 
focused on chromosome instability and genomic alterations in established tumor 
inducing and maintaining pathways. Comparative genomic hybridization (CGH) 
was the first method used in multiple analyses of numeric chromosomal 
aberrations in gastrointestinal NETs with loss of chromosome 18 considered a 
breakthrough discovery.[21-25] Besides, distinct chromosomal gains (4, 5, 19, 20q) 
were common events in several GEP-NETs. Gains of the long arm of 
chromosome 20 as the most frequent amplification in foregut NETs (58%) for 
instance represented a considerable part of midgut NET alterations (36%). On 
the contrary, some other chromosomes were multiplied by preference in foregut 
(17p) or midgut (17q, 19p).[22] Figure 7 illustrates the frequency of chromosome 




Figure 7. Frequency of chromosomal aberrations in gastrointestinal NETs. Comparison of highly frequent 
(bottom) and less frequent events (top).[26] 
 
Loss of heterozygosity of tumor suppressor genes located on chromosome 18 is 
estimated a major candidate in driving SI-NET tumorigenesis, just as in other 
gastrointestinal tumor species.[27] Therefore, the working group of Prof. Sipos 
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analyzed seven tumor suppressor genes located on chromosome 18 in SI-NETs 
via Immunohistochemistry (IHC) and Western Blot revealing a reduced 
expression of DCC (Deleted in Colorectal Cancer gene) in about 30% of the 
investigated samples. 
The previously identified chromosomal aberrations were confirmed by Banck et 
al. through DNA investigation of 48 patients with SI-NETs by whole exome 
sequencing (WES), the first genome-wide analysis comprising more than 20,000 
genes.[28] Figure 8 compares spotted chromosomal gains (most notably in 
chromosome 4, 5, 14 and 20) and losses (predominantly chromosome 18).  
 
 
Figure 8. Quantity of chromosomal alterations in SI-NETs. Signal gains (red, above midline) and losses 
(blue, below midline) detected by whole exome sequencing are displayed for each chromosome    
separately.[28] 
 
Abnormalities of particular chromosomes (loss of 18q and 11q) have been 
considered as early events of malignant transformation, whereas other 
chromosomal alterations (loss of 16q and gain of 4p) predominantly found in 
metastases seem to be late events and markers of tumor progression.[25] In 
several cases, copy number gains affected at least chromosome 4 and 20 
simultaneously and were almost always correlated with a loss of chromosome 
18, whereas chromosome 18 losses in many cases occurred isolated.[29] This 
confirmed that different mechanisms lead to early and late events, respectively. 
Also, genetic heterogeneity was seen as indicative of different neoplastic cell 




At molecular level, Banck et al. revealed somatic copy number variations and 
mutations in several cancer-related signaling pathways. For example, they found 
alterations in PI3K / AKT / mTOR signaling, which cause apoptosis escape and 
can immortalize tumor cells. This finding corresponds with positive clinical effects 
of mTOR-inhibitor Everolimus in other types of GEP-NETs (unlike SI-NETs). 
Spotted gains in signal associated genes like EGFR (Epidermal growth factor 
receptor), PDGFR (Platelet derived growth factor receptor) and mutations in 
FGFR2 (Fibroblast growth factor receptor 2) could also explain dysregulations of 
this pathway.[28]  
In addition, copy number gains were detected in proto-oncogenes, most 
frequently in SRC (encoding for Src tyrosine kinase) and its downstream 
effectors.[28]  
Inactivating mutations of CDKN1B (encoding for Cyclin dependent kinase 
inhibitor 1B) and gains in AURKA (encoding for Aurora A serine / threonine 
kinase) are two examples of reported alterations in cell cycle regulators as major 
source of genetic instability in SI-NETs.[28,29]  
The identified genomic alterations in SI-NETs widely vary from other GEP-NETs. 
Pancreatic NETs, for example, represent the greatest part of NETs associated 
with inherited syndromes, most commonly MEN1.[31] MEN1, a tumor suppressor 
that represses telomerase activity, is most frequently inactivated in pancreatic 
NETs. The second most common mutations concern ATRX / DAXX, encoding for 
a chromatin remodeling complex.[32] Inactivation of this complex modifies 
telomeric chromatin and leads to alternative lengthening of telomeres (ALT). This 
constitutes an essential mechanism of tumor cell immortality.[33] Moreover, 
gastrointestinal NETs for their part are based on different molecular conditions 
than NETs of other provenance. This concerns distribution patterns of 
chromosomal aberrations; for example the most frequent event in GEP-NETs is 
loss of chromosome 18, whereas bronchial NETs most of all feature loss of 
chromosome 11 and chromosome 18 is preserved.[24,34] Beyond, alterations of 
MEN1 (located on chromosome 11), seem to be likewise involved in sporadic 
bronchopulmonary NETs but less likely in gastrointestinal NETs.[35,36] This 
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assumes that clinical appearance and outcome is determined by different 
molecular mechanisms. NETs should therefore no longer be seen as one entity. 
1.3. AURKA 
The human Aurora kinase enzyme family consists of Aurora kinase A, B and C; 
all nonspecific serine/threonine kinases holding a regulatory function in cellular 
division. These proteins correspond in the C-terminal position of their catalytic 
domains but vary in length, subcellular compartment, function and the localization 
of their encoding genes (AURKA, AURKB, AURKC).  
AURKA, encoding for Aurora kinase A is located on the chromosomal region 
20q13.2 measuring 22,949 bp. The protein consists of 403 amino acids with a 
total molecular mass of 45.8 kDa and is expressed in the nucleus, cytosol and 
centrosome of proliferating cells in many tissues (most notably in brain and the 
gastrointestinal system). As one of the key mitotic regulators it is highly expressed 
between the S and M phase and is involved in the centrosome maturation, mitotic 
entry, microtubule assembly and stabilization of the bipolar spindle apparatus 
required for correct chromatid segregation, and cytokinesis.  
Aurora A activity depends on its expression degree and is terminated by 
anaphase-promoting complex / cyclosome (APC / C) ubiquitination and 
proteasome degradation when mitosis is completed.[37] Enzyme activity is 
temporally controlled by different phosphorylation mechanisms at Thr288 including 
protein kinase A (PKA), whereas phosphorylation can be reversed by protein 
phosphatase 1 (PP1). It is spatially regulated by auxiliary agents such as TPX2 
(Target protein for Xenopus kinesin-like protein 2) relocating the protein to the 
spindle and centrosome and potentiating the enzyme capacity via 
autophosphorylation and PP1 antagonism.[38] 
First observed in breast and colorectal malignancies, AURKA amplification and 
protein overexpression has been found in many cancer types, such as ovarian, 
cervical or prostate tumors and subsequently was demonstrated to cause in vitro 
and in vivo malignant transformation in human and rodent cell lines.[39,40] The 
enhanced expression, however, is only partially ascribed to gene amplification. 
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This is exemplified by a CGH study on gastric cancer, in which AURKA 
overexpression was identified in 50% of the cases, whereas only 5% showed 
gene amplification as well.[41] Presenting with regular copy numbers it can 
likewise be generated by intensified transcription, aberrant activation (for 
example by phosphorylation site mutations) or interactions with regulatory genes 
or proteins like PP1.[42] Intensified interactions which already existed and newly 
acquired ones could both account for the nuclear and cytoplasmic excess of 
Aurora A during the entire cell cycle in cancer cells.[43]  
Excessive Aurora A activity intensifies the G1 / S cell cycle shift by up-regulation 
of cyclins and cyclin dependent kinases; firstly, by transcript polyadenylation and 
secondly, by enforced activation of polo-like kinase 1 and its downstream 
proteins.[43-45] Moreover, Aurora kinases are suspected to overregulate H3 
histone phosphorylation conditioning the mitotic entry.[37] Elevated Aurora kinase 
A levels also assist in skipping mitotic spindle checkpoints which monitor the 
correct chromosomal alignment.[46] In normal cells, a feedback system between 
Aurora A and the tumor suppressor p53 (most important damage-related 
mediator of apoptosis) keeps cell growth and death in balance. If overexpressed, 
Aurora A defies this control mechanism by phosphorylating and thereby 
inactivating p53.[47] Cells with poorly aligned chromosomes are thus still able to 
multiply.  
In summary, overexpression of Aurora kinase A has been observed to accelerate 
cell proliferation with amplified centrosomes, irregular spindles, chromatid mis-
segregation, failure in cytokinesis and decreased apoptosis, as illustrated in 
Figure 9.[44] This explains the oncogene-like function of AURKA in carcinogenesis 






Figure 9. Centrosome and spindle organization during mitosis. a) Cells with balanced AURKA levels and 
normal chromosome 20 divide regularly (green). b) Cells with AURKA amplification or increased protein 
activity with disrupted mitotic spindles result in chromosomal missegregation or aneuploidy (pink). Modified 
according to ref. [38,45]. 
 
Increased Aurora A expression additionally has two detrimental consequences. 
First, it interacts with cancer-driving proteins: Aurora A-induced phosphorylation 
up-regulates NF-κB (nuclear factor κ B) by degradation of NF-κB inhibitor α 
(NFKBIA), it activates AKT1 and it stimulates the RAS pathway via Ras like proto-
oncogene A (RALA), which jointly enhances cell survival, proliferation and 
motility.[48] Second, it cuts cancer treatment response by inducing resistance to 
tubulin-targeting chemotherapy like Paclitaxel and reducing apoptotic response 
to Cisplatin, both of which are used for many of the previously mentioned tumor 
types.[46,47] Therefore, AURKA amplification or overexpression could serve as 
predictive biomarker. But most importantly, this fact points out the attractiveness 
of simultaneously stopping tumor progression and improving overall treatment 
results with appropriate enzyme inhibitors. 
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Inspired by the success of state-of-the-art immunotherapy, multiple Aurora kinase 
inhibitors have been designed and are currently tested in preclinical and clinical 
trials. For unresectable, previously unmanageable SI-NETs, the phase II 
candidate drugs Alisertib (MLN8237) and Danusertib (PHA-739358) open up new 
treatment perspectives.[49] In vivo experiments of human GEP-NET cell lines 
expressing Aurora kinase A demonstrated tumor growth reduction and lower 
levels of biomarkers after Danusertib application in a xenograft mouse model. 
These results were confirmed by a cell-cycle arrest in vitro.[50] With limited 
adverse drug effects (neutropenia) this target therapy is generally well tolerated.  
1.4. SRC 
SRC is part of the first identified proto-oncogenes. It was discovered by Michael 
Bishop and Harold Varmus, who were jointly awarded the Nobel Prize in 
Physiology or Medicine in 1989 for their findings on the origin and impact of 
oncogenes.[51] SRC encodes for non-receptor tyrosine kinase SRC, head of the 
Src kinase family including other structurally resembling proteins (FYN, YES, 
YRK, BLK, FGR, HCK, LCK and LYN). First isolated as viral SRC mutant (v-SRC) 
from the Rous sarcoma virus (avian retrovirus) SRC’s provenance has been 
identified as cellular gene in vertebrates (c-SRC, in short: SRC).[52]  
SRC is mapped to the chromosomal region 20q11.23 and has a size of 61,366 
bp. The 59.8 kDa protein composed of 536 amino acids is characterized by 
cytoplasmic and membranous expression in neurons, thrombocytes and 
proliferating cells of many tissues (predominantly in adrenal glands, the bronchial 
system and reproductive organs). [53,54]  
Enzyme activity is initiated during the G2/M cell cycle transition by 
phosphorylation at Tyr416 (either autophosphorylation or via intramolecular 
conformational changes) subsequent to activation of different receptors. The 
most important receptor classes in this context are receptor tyrosine kinases 
(mainly EGFR and PDGFR), cytokine receptors like Receptor Activator of 
Nuclear Factor κ B (RANK) and integrins (mediators of cell-cell and cell-matrix 
contacts). Moreover, SRC is regulated by cell adhesion molecules (CAMs), G-
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protein-coupled receptors (such as β-adrenergic receptors) and steroid receptors 
(for example by the progesterone receptor).[55] SRC and its activating receptors 
underlie remarkable mutual regulation.[56] Therefore, it represents an interface 
between extracellular signals and cellular signal transduction pathways.  
Once activated, it phosphorylates cellular proteins at specific tyrosine residues. 
These proteins consequently interact with effectors of diverse biological 
procedures, most importantly gene transcription, cell differentiation, proliferation, 
survival, cell-cell adhesion, migration and angiogenesis.[57] Figure 10 exemplifies 
SRC’s interactive network highlighting the complexity of cross-talking pathways. 
All of these physiological functions can contribute to malignant transformation 
and metastatic spread if running out of control. In contrast to the constitutively 
active viral oncogene, cellular Src kinase can be inhibited via phosphorylation at 






Figure 10. Simplified examples of SRC-mediated signal transduction pathways. Extracellular ligands bind 
to transmembrane protein receptors. When activated, SRC phosphorylates diverse targets transducing 
these signals into cellular pathways of angiogenesis, proliferation, survival, migration and cell adhesion. 
 
Many tumors (especially breast, colorectal, prostate, pancreatic and gastric 
carcinoma) are associated with amplifications and / or overexpression of SRC, 
and are also related to elevated levels of growth factors and SRC’s downstream 
proteins such as focal adhesion kinase (FAK) and signal transducer and activator 
of transcription 3 (STAT 3).[59] In hepatocellular carcinoma, increased SRC 
activity has been observed as a result of reduced levels of inhibitory CSK.[60] By 
contrast, colorectal cancer is associated with activating mutations.[61] However, 
elevated SRC expression is unlikely to directly condition cancer cell growth.[59] 
Instead, up-regulation of downstream proteins allows for growth factor 
independency and stepwise facilitates tumor progression from immortalization of 
malignant cells to invasion and metastases.[62]  
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In order to provide a better understanding of SRC’s role in cancer, exemplary 
SRC-mediated signaling pathways and their impact on carcinogenesis are 
discussed in the following.  
One of Src kinase’s major functions is the control of cytoskeleton arrangement. 
This is achieved by close cooperation with growth factors (for example EGF) and 
integrins in contact with p190 Rho GTPase activating protein (antagonizes Rho-
dependent contractility), cortactin and focal adhesion proteins like FAK or 
paxillin.[62] The relation of SRC and EGF was clarified in breast cancer showing 
abundant activity of both factors with SRC potentiating the mitogenic 
responsiveness to EGF stimulation.[63]  
FAK, one of SRC’s key binding partners bundles integrin- and growth factor-
induced signals required for cell dispersion, morphological change and 
accelerated division.[64] In case of disrupted signaling, it seems to enhance tumor 
cell sensitivity for misguided migration and epithelial-mesenchymal transition.[65]  
Cell integrity is further maintained by SRC’s regulation of the β-Catenin /                
E-Cadherin complex. Phosphorylation of this cell-cell adhesion complex by 
constitutively active Src kinase results in an impairment of cell differentiation, 
dissemination and invasiveness.[66]  
Moreover, SRC stimulates STAT- and VEGF- driven angiogenesis and vascular 
permeability.[67] 
By regulating the PI3K / AKT pathway, SRC influences a diversity of cellular 
events like cell adhesion and migration, differentiation, DNA synthesis and most 
of all survival which is also an objective of Cyclooxygenase 2 (COX2) 
stimulation.[56]  
SRC activating the RAS / MAPK pathway with subsequently induced transcription 
factors for cell growth, division and apoptosis like STAT 3, MYC or FOS and their 
control of cyclins and cyclin dependent kinases represents a major proliferation 
stimulus.[55,62] 
All in all, SRC’s interactive properties enlarge the signals of affiliated pathways 
creating synergistic effects.[56] 
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Inhibiting Src kinase therefore seems to be a therapeutic rationale. Dasatinib 
(BMS-354825) and Bosutinib (SKI-6606), the two best studied SRC (and BCR-
ABL) tyrosine kinase inhibitors, are FDA approved for hematologic malignancies 
and are currently tested in solid cancers like breast, colon and prostate 
carcinoma.[59] Human cell lines derived from these solid cancer types not only 
showed suppressed proliferation, but also a decline in dysfunctional adhesion, 
migration and invasiveness after being exposed to Dasatinib.[68,69] SRC inhibitors 
prevented primary tumor growth and metastatic spread in mice with prostate 
carcinoma xenografts in vivo.[70] In a pancreatic adenocarcinoma mouse model, 
Dasatinib inhibited metastases and reduced the primary tumor size, which 
emphasizes its better success in cutting dissemination than in suppressing tumor 
emergence.[62,71] Regarding SI-NETs, SRC inhibition in vitro and in vivo arrests 
tumor growth.[72] 
Due to its clinical effectiveness and tolerability in phase 1 and phase 2 trials with 
adverse effects comparable to other therapies (fatigue, neutropenia, pleural 
effusion), Dasatinib is soon expected to be FDA approved for solid tumors.[73] 
On one hand, cytostatic SRC blockade is worrisome because of the wide range 
of affected downstream proteins, of which many are required for essential cell 
activities. On the other hand, synergistic anti-cancer effects have been noticed 
resulting from mutual inhibition of SRC and its closely related signaling partners. 
As an example, silenced SRC increased the sensitivity to Cetuximab (EGFR 
inhibitory monoclonal antibody) in colorectal carcinoma and non-small cell lung 
cancer in preclinical studies.[74,75] Since many of Src’s activators are receptor 
tyrosine kinases, multikinase inhibition could amplify the effect of blocking SRC’s 
excessive activity. 
1.5. Aim of the thesis 
Neuroendocrine tumors of the small intestine are rare but represent the most 
frequent small bowel malignancy. Their late manifestation associated with an 
extensive metastatic spread has a limiting impact on surgery as the only curative 
treatment. It is obvious that a better understanding of the molecular mechanisms 
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underlying these tumors is required for the development of promising targeted 
therapies. 
AURKA as a key mitotic regulator gene and SRC as one of the first discovered 
proto-oncogenes have been identified as amplified and / or overexpressed in a 
variety of malignancies. This thesis, in particular, focuses on AURKA and SRC 
alterations in SI-NETs and on numeric aberrations of chromosome 20 which 
harbors both genes. Since the whole exome sequencing study by Banck et al. 
comprised a small cohort of only 48 patients, the analysis of AURKA and SRC’s 
roles in the emergence of SI-NETs is extended in this thesis.[28] For this purpose, 
217 tissue samples of 135 patients, arranged as Tissue Microarrays (TMAs) were 
examined by fluorescence in situ hybridization (FISH). Protein expression levels 
of AURKA and SRC were determined via immunohistochemistry (IHC). 
Moreover, catalytic activity was examined with specific antibodies targeting 
phosphorylation site Thr288 for AURKA and Tyr527 for SRC.  
Since the inhibition of protein kinases achieved therapeutic success in various 
cancer types, Aurora A inhibitors like Alisertib and Danusertib are currently tested 
in advanced clinical trials showing considerable effects in vitro and in vivo. Src 
tyrosine kinase inhibitors such as Bosutinib and Dasatinib are already FDA 
approved and in clinical use.  
With regard to new potential approaches to SI-NET therapy, it is of great 
importance to verify the reported alterations using different methods.[28] An 
understanding of how these alterations affect tumor emergence and progression 
could provide additional information for optimizing the therapeutical schedule. 
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2. Material and methods 
2.1. Patients and samples 
For this investigation, 217 SI-NET samples were gained by surgical resection 
including 128 primary tumors (from the jejunum, ileum and the iliocaecal valve), 
74 lymph node metastases and 15 distant (mostly hepatic) metastases from 135 
patients. In many cases, patients provided a primary tumor and its corresponding 
node and / or distant metastasis.  
The study obtained ethical approval from the local ethics committee at the 
University Hospital of Tuebingen (469 / 2010BO2). 
After formalin fixation, paraffin embedding and hematoxylin and eosin (H&E) 
staining, the samples were evaluated as well-differentiated tumor tissue 
according to the WHO classification by a pathologist via light microscopy at the 
pathology departments of Tuebingen, Munich, Duesseldorf or Marburg. Then the 
tissue was staged according to the UICC TNM criteria and additionally classified 
by an internal score with the first group (encoded 1) listing all UICC stages 
separately, the second group (encoded 2) combining UICC stages I to IIB (other 
stages separately) and the third group (encoded 3) combining UICC stages I to 
IIIA (other stages separately).  
Depending on tumor spread at the time of diagnosis the patients were grouped 
into three cohorts; (1) patients with only primary tumors, (2) patients with 
additionally lymph node metastases and (3) patients with both node and distant 
metastases.    
2.2. Tissue microarray 
Formalin-fixed paraffin-embedded (FFPE) tissues (see 2.1. Patients and 
samples) were used to fabricate eight tissue microarrays (TMA) by Christine 
Beschorner and Dr. Maike Nieser (working group of Prof. Sipos). Tissue samples 
with a size of 1 mm were taken from donor paraffin blocks and placed into pre-
punched gaps of recipient paraffin blocks in duplicate (TMA 6, 7, 8) and in 
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triplicate (TMA 11.1, 11.2, 12, 13, 14) using a tissue microarrayer (Beecher 
Instruments, WI, USA) and MTABooster (Alphelys, Plaisir, France). TMA grid 
layouts were created with the TMA Designer 2 software (Alphelys, Plaisir, 
France). The recipient paraffin blocks were first treated at 56 °C for 10 minutes 
and subsequently at 4 °C for 30 minutes. This sealing procedure was repeated 
twice. For both immunohistochemistry and fluorescence in situ hybridization, thin 
sections of 3 or 3.5 µm were separated from the TMA blocks and applied on 
SuperFrost Plus slides (Langenbrinck, Emmendingen, DE).  
2.3. Chemicals and equipment 
Table 4. Chemicals 
Chemicals Manufacturer 
Double-distilled water (ddH2O) Merck (Darmstadt, Germany) 
Ethanol 100% Merck (Darmstadt, Germany) 
Hydrogen peroxide 30% Merck (Darmstadt, Germany) 
Pepsin Sigma-Aldrich (St. Louis, MO, USA) 
ProLong® Gold Antifade mountant with 
DAPI 
Thermo Fisher Scientific (Waltham, MA, 
USA) 
Sodium chloride Merck (Darmstadt, Germany) 
Sodium citrate Sigma-Aldrich (St. Louis, MO, USA) 
Xylene AnalaR NORMAPUR ACS VWR Chemicals (Radnor, PA, USA)  
Zytochem-Plus HRP Polymer-Kit Zytomed Systems (Berlin, Germany) 
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Table 5. Buffers 
Buffers Manufacturer / Composition 
Ammonia solution 25% Merck (Darmstadt, Germany) 
Papanicolaou's solution 1a Harris' 
hematoxylin solution 
Merck (Darmstadt, Germany) 
Wash buffer (20x) Zytomed Systems (Berlin, Germany) 
Citrate buffer (10x, pH 6) 29.4 g Trisodium citrate dihydrate               
ad 1 l ddH2O 
Post-hybridization wash buffer         
(0.3% NP-40 / 2x SSC) 
100 ml 20x SSC (pH 5.3)                                 
3 ml NP-40                                                    
ad 1 l ddH2O 
Saline sodium citrate (SSC) buffer    
(20x, pH 7.4) 
175.32 g Sodium chloride 
88.23 g Sodium citrate  
ad 1 l ddH2O 
TEC buffer (10x, pH 9) 2.5 g Tris(hydroxymethyl)aminomethane                                                    
5 g Ethylene diamine tetraacetic acid                                                      
3.2 g Trisodium citrate dihydrate                 
ad 1 l ddH2O 
 
Table 6. Consumable supplies 
Consumable supplies Manufacturer 
Cover slips Menzel (Braunschweig, Germany) 
Glass slides R. Langenbrinck (Emmendingen, Germany) 
Pipettes (10 µl, 100 µl, 200 µl, 1000 µl) Eppendorf (Hamburg, Germany) 
Pipette tips Starlab (Blakelands, UK) 
Reaction tubes 1.5 / 2 ml Eppendorf (Hamburg, Germany) 
SuperFrost Plus slides  R. Langenbrinck (Emmendingen, Germany) 
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Table 7. Equipment 
Equipment Manufacturer 
AxioCam MRm Carl Zeiss MicroImaging (Goettingen, 
Germany) 
Centrifuge Eppendorf (Hamburg, Germany) 
Fluorescence microscope Axio Imager 
M2 
Carl Zeiss MicroImaging (Goettingen, 
Germany) 
Microscope Carl Zeiss (Jena, Germany) 
MiraxDesk Scanner Carl Zeiss (Jena, Germany) 
ThermoBrite Stat Spin Abbott Molecular (Abbott Park, IL, USA) 
Thermomixer Comfort Eppendorf (Hamburg, Germany) 
Tissue Microarrayer Beecher Instruments (Sun Prairie, WI, 
USA) 
Ventana BenchMark System Ventana Medical Systems (Tucson, AZ, 
USA) 
Vortex mixer IKA (Staufen im Breisgau, Germany) 
Water bath GFL Gesellschaft für Labortechnik 
(Burgwedel, Germany) 
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Table 8. Antibodies / Probes 
Antibodies / Probes Manufacturer 
AURKA (polyclonal antibody produced 
in rabbit) #HPA002636 
Sigma-Aldrich (St. Louis, MO, USA) 
p-AURKA (pT288, polyclonal antibody 
produced in rabbit) #PAB25906 
Abnova (Taipei City, Taiwan) 
p-SRC (Y527, polyclonal antibody 
produced in rabbit) #2105S 
Cell Signaling Technology (Danvers, 
Massachusetts, USA ) 
SRC (36D10, monoclonal antibody 
produced in rabbit) #2109 
Cell Signaling Technology (Danvers, 
Massachusetts, USA) 
AURKA / CEN20p FISH probe 
#FG0132 (Texas Red / FITC) 
Abnova (Taipei City, Taiwan) 
CEN20q FISH probe #FC0166 (FITC) Abnova (Taipei City, Taiwan) 
SRC / CEN20p FISH probe #FG0175 
(Texas Red / FITC) 
Abnova (Taipei City, Taiwan) 
 
Table 9. Software 
Software Manufacturer 
MTABooster Alphelys (Plaisir, France) 
Tissue Studio XD 2.3.0 Definiens (Munich, Germany) 
TMA Designer 2 Alphelys (Plaisir, France) 
SPSS Statistics 24 IBM (Armonk, NY, USA) 
 
2.4. Fluorescence in situ hybridization 
Fluorescence in situ hybridization (FISH) is a diagnostic and clinical research 
technique based on the binding of labeled DNA or RNA sequences to target 
genes or chromosome segments in interphase or metaphase cells allowing for 
the investigation of genetic aberrations. In particular, short locus-specific 
complementary single-stranded DNA sequences (probes) are used to detect the 
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location, gain or loss of genes and structural or numerical chromosomal 
abnormalities. In cancer diagnosis and therapy, FISH can determine the 
etiopathogenesis and the progression level of a disease.[76]  
For the preparation process the probes have to be isolated from fragmented DNA 
gained from plasmids, cosmids, several artificial chromosomes like yeast artificial 
chromosomes (YACs) and other sources.[77] When processed and amplified, a 
fluorescent dye is added to the probes in order to localize the hybridization. 
Therefore, the probes are labeled by chemical or enzymatic reactions such as 
nick translation or polymerase chain reaction (PCR) and are either directly 
marked by fluorophores or indirectly by attaching them to a hapten reporter 
molecule such as biotin, dioxigenin, aminoacetylfluorene, dinitrophenyl or 
sulfonate tagged with an antibody binding a corresponding fluorescence marked 
anti-immunoglobulin.[78] The most typical fluorescent dyes are Texas Red, 
fluorescein isothiocyanate (FITC) and rhodamine. Figure 11 illustrates the 
hybridization of the target DNA and the labeled probe. 
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Figure 11. Fluorescence in situ hybridization technique. The probe is either marked with a fluorophore or 
with a fluorophore bound to a hapten, signaling the existence / quantity of the target. Modified according to:  
http://www.abnova.com/images/content/support/FISH_brochures.pdf. Date accessed: 06/04/2017.  
 
This method can be used for the analysis of both paraffin-embedded and frozen 
tissue.  
In this study, FISH was performed following the protocol given below. In order to 
examine SRC and AURKA and compare the count of chromosome 20 in formalin-
fixed and paraffin-embedded TMAs, Abnova AURKA/CEN20p FISH probe 
#FG0132 and Abnova SRC/CEN20p FISH probe #FG0175 (Taipei City, Taiwan) 
were used, both of which are mixtures with one probe targeting the gene of 
interest and the other one the corresponding chromosomal centromere. 
Additionally, chromosome 20 was tested with the Abnova CEN20q centromere 
FISH probe #FC0166. 
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Protocol for FISH (Abnova). During paraffin-embedded tissue pretreatment, the 
samples first were deparaffinized in xylene three times for five minutes each at 
room temperature. Then they were immersed in 100% ethanol twice for five 
minutes each at room temperature and air-dried. Afterwards, the slides were 
treated with a sodium citrate paraffin pretreatment solution at 95°C for 30 minutes 
and subsequently washed with a saline sodium citrate wash buffer (2 x SSC) for 
five minutes twice. To improve the DNA accessibility and reduce background 
such as cytosolic auto fluorescence the samples were treated with a pepsin 
solution as digestive protease treatment at 37°C for six minutes and subsequently 
washed (see above). Regarding tissue integrity, excessive protease treatment 
generally should be avoided. The last step of the pretreatment consisted of tissue 
dehydration in 70% ethanol and then in 100% ethanol for one minute each at 
room temperature and air-drying. 
After applying the FISH probe (in this case 10 μl for a 22 x 22 mm tissue area) 
the slides were covered with cover glass, sealed with rubber cement and 
denatured at 75°C for 5 minutes.  
The denatured target DNA was incubated with the probe in a humidified box at 
37°C for 48 hours, which allowed for the hybridization of their single strands 
through the formation of hydrogen bonds. 
Post-hybridization washing was used to remove residual DNA and probe. For this 
purpose, rubber cement and cover glass were removed, the samples were 
washed with 2 x SSC wash buffer for five minutes at room temperature, then with 
post-hybridization wash buffer 2 x SSC / 0,3% NP-40 at 73°C for two minutes and 
lastly with 2 x SSC wash buffer for one minute at room temperature. 
Eventually, the target area was counterstained with 10 μl DAPI (4’6’-Diamidine-
2’-phenylindole dihydrochloride), cover slipped and sealed with manicure.  
FISH evaluation. To evaluate the FISH, signals were examined in at least 30 
cells per sample via fluorescence microscopy with a Zeiss Axio Imager M2 
microscope (Oberkochen, Germany) equipped with a double filter for the 
simultaneous view of gene signals for AURKA or SRC (Texas Red) as well as 
the signal for chromosome 20 (FITC). Assuming there are two alleles of each 
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gene in a normal cell, 60 signals in 30 examined cells were considered as normal 
gene / chromosomal status. More signals (threshold was set at >72 target gene 
signal counts) could be ascribed to specific gene amplification or to polysomy, 
i.e. the presence of one or more additional chromosomes. Due to this 
differentiation, statistical analysis required a numeric relation of the target gene 
and the respective chromosome signal. Since chromosome 20 signals could not 
be consistently evaluated, setting up this ratio was not possible. Instead, the 
ratios of AURKA signals to SRC signals and vice versa were calculated with the 
denominator giving an estimation of the centromere signal. In this way, specific 
gene amplification was defined as ≤ 72 estimated centromere signal counts with 
a target to estimated centromere signal ratio > 1.2. In contrast, centromere 
signals > 72 with a ratio ≤ 1.2 were specified as polysomy. In case of 
simultaneous gene amplification and polysomy, centromere signal counts were > 
72 with a ratio > 1.2.  
2.5. Immunohistochemistry 
Immunohistochemistry (IHC) is a tissue staining method combining immunology, 
histology and chemistry by using antibody-linked dyes to highlight antigens, i.e. 
specific structures within a tissue. There are different principles of 
immunostaining. Antibodies binding to epitopes are either directly marked or their 
Fc fragment is bound to a labeled secondary antibody. More precisely, the 
antibody is covalently bound to a catalytic enzyme, such as peroxidase or alkaline 
phosphatase. Once the antibody binds to the respective epitope the featured 
enzyme catalyzes a chromogenic substrate reaction with the oxidation of the 
chromogen (for example 3,3’ Diaminobenzidine or 3-Amino-9-Ethylcarbazole) 
resulting in a color signal. The signal can be amplified by tagging the antibody 
with a biotin-avidin complex, a biotin-streptavidin complex or with a polymer-
based detection system. Antibodies are mostly produced in rabbits or mice and 
can be both monoclonal (high specificity for a single epitope) and polyclonal 
(lower specificity and higher likelihood of cross-reaction with similar epitopes).[79] 
Figure 12 illustrates the different immunohistochemical staining methods. 




Figure 12. Immunohistochemical staining methods. Direct method, indirect method and signal amplification. 
Modified according to: http://www.immunohistochemistry.us/immunohistochemistry-staining.html  
and https://www.novusbio.com/ihc-detection. Date accessed: 06/04/2017. 
 
As a standard diagnostic method, immunohistochemistry is used to trace the 
origin of tumors and infectious diseases.[80] There are specific 
immunohistochemical markers for various neoplasms. Specific clusters of 
differentiation are for example indicative of hematopoietic and lymphoid 
malignancies, whereas cytokeratins mark epithelial tumors.[81] In addition, 
immunohistochemistry can determine apoptosis, mitosis or proliferation with 
particular markers of which Ki-&7 is a well-known representative.[82,83] As a result, 
it improves the assessment of a disease’s characteristics so that it can be 
classified, given a prognostic value and a predicted treatment response.[84]  
The method can be applied to frozen tissue and formalin-fixed paraffin-embedded 
tissue.  
In this study, the samples were examined for AURKA (nuclear and cytoplasmic) 
and SRC (cytoplasmic) expression. Phospho-AURKA und phospho-SRC were 
also tested but did not show remarkable results. For this purpose, tissue was 
immunostained with Sigma-Aldrich AURKA Cat#HPA002636 (St. Louis, USA), 
Abnova phospho-AURKA (pT288) Cat#PAB25906 (Taipei City, Taiwan), both 
polyclonal antibodies produced in rabbits, Cell Signaling SRC (36D10, 
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monoclonal antibody produced in rabbits) Cat#2109 and Cell Signaling phospho-
SRC (Y527, polyclonal antibody produced in rabbits) Cat#2105S (Cambridge, 
UK) at the Institute of Pathology, University of Tuebingen. The AURKA antibody 
was established on a colon carcinoma TMA which was also used as positive 
control due to its close resemblance to tissue of the small intestine. For the SRC 
antibody tonsil tissue was used as positive control because of strong cytoplasmic 
SRC expression in lymphoid tissue. The antibody was also established on a tonsil 
block. The slides were stained both manually and with an autostainer (Ventana 
BenchMark System,Tucson, USA) for checking purposes. 
Protocol for IHC. Starting with a paraffin-embedded tissue pretreatment, the 
samples were deparaffinized in xylene three times for 15 minutes each at room 
temperature. For rehydration, they were immersed for three minutes in 100% 
ethanol twice, for three minutes in 96% ethanol twice and for three minutes in 
75% ethanol. To inactivate the endogenous peroxidase, the slides were 
incubated with 3% hydrogen peroxide in 75% ethanol for five minutes. 
Afterwards, the slides were rinsed in distilled water for five minutes. 
The epitopes were retrieved with a heat-based treatment reversing the cross-
links formed during fixation. For this purpose, the samples were boiled in sodium 
citrate (pH 6, for AURKA) and TEC (pH 9, for SRC) buffer for five minutes. After 
cooling down for 20 minutes, the slides were briefly immersed in distilled water 
and rinsed in wash buffer for three minutes twice. 
For hybridization, antibodies were applied overnight. The next day, the slides 
were rinsed in wash buffer for five minutes, followed by the application of the 
secondary antibody (PostBlock) for 30 minutes, re-washing (see above) and the 
application of the horseradish peroxidase polymer (HRP) conjugate for another 
30 minutes. After re-washing (see above) the tissue was covered with 3,3’ 
Diaminobenzidine (DAB) for five minutes twice. The oxidation of DAB catalyzed 
by HRP caused a brown staining. 
Subsequently, the samples were re-washed, briefly immersed in distilled water 
and then counterstained with Papanicolaou’s solution for 15 seconds enhancing 
cell identification. Afterwards, the slides were briefly rinsed in distilled water three 
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times, then immersed in an ammonia solution (6 ml 3% ammonia in 200 ml 70% 
ethanol), followed by dehydration in 70% ethanol for two minutes, 80% ethanol 
for two minutes, 96% ethanol for two minutes twice, 100% ethanol for two minutes 
four times and xylene for two minutes four times. Eventually, a cover slip was 
applied. 
IHC evaluation. The immunostainings were analyzed using light microscopy 
(Carl Zeiss, Oberkochen, Germany). For AURKA the staining intensity ranged 
from 0 to 3 (0: negative, 1: weakly, 2: moderately, 3: strongly positive) for both 
nuclear and cytoplasmic signals. For SRC, the immunoreactive score (IRS) was 
used taking account of the cytoplasmic staining intensity (0: negative, 1: weakly, 
2: moderately, 3: strongly positive) multiplied with the quantity of positive cells (0: 
none, 1: <10%, 2: 10-50%, 3: 51-80%, 4: >80%). The results ranging from 0 to 
12 were evaluated according to the Remmele score (0-2: negative, 3-4: weakly, 
6-8: moderately, 9-12: strongly positive) and via dichotomic division (0-6: 
negative – moderate and 7-12: strong). 
Additionally, the AURKA slides were scanned (MiraxDesk Scanner, Carl Zeiss, 
Jena, Germany) and evaluated with Tissue Studio XD 2.3.0 (Definiens, Munich, 
Germany). This software provided quantitative tissue analysis by scaling the 
staining extent and intensity of nuclear antigens in relation to the total area of 
selected regions of interest. The thresholds of weak to moderate and moderate 
to high hematoxylin and IHC staining intensity were set with the nucleus 
classification tool. As a result, the percentage of moderately and strongly AURKA 
expressing cells compared with all investigated cells was calculated as a 
quantitative reference for the manual evaluation. Figure 13 visualizes the 
Definiens Tissue Studio workflow starting with an appropriate grid view selection 
(a) proceeding to the nucleus detection (b) and intensity classification (c), which 
enabled the final calculation. 
Since this software only provides reasonable results for nuclear protein 
expression it could not be applied to SRC evaluation.  
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Figure 13. Definiens Tissue Studio 2.3.0. workflow. a) Qualified samples are chosen with a grid view 
selection, b) nucleus detection determines nuclear morphologies, c) staining intensity thresholds are set by 
nucleus classification. 
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2.6. Statistical analysis 
The findings for AURKA and SRC provided by FISH and IHC were statistically 
tested for correlations between amplification and overexpression depending on 
the spreading progress of the tumors. Thereby, the results for (1) primary tumors, 
(2) lymph node metastases, (3) distant metastases and (4) any clinical case 
(irrespective of the origins mentioned before) were separately examined.  
As part of this analysis, FISH copy numbers were compared to IHC results via 
Pearson’s chi-square test in two different settings. First, the IHC results were split 
up by the immunoreactive score (IRS) into negative and weakly stained (IRS 0-
3) on one hand and moderately and strongly stained (IRS 4-12) on the other. 
Second, the results were organized dichotomously (IRS 0-6 and 7-12). 
Similarly, Pearson’s chi-square test was applied for the analysis of associations 
with other clinical characteristics. 
The relation of FISH results and overall survival was analyzed with the Kaplan-
Meier estimator. 
Statistic dependencies were evaluated with SPSS (Statistics 24, IBM, Armonk, 




3.1. Patient and tumor specifications 
In consideration of available data, 52% of the tissue donating SI-NET patients 
were male, 48% were female. The average age was 59 years with a standard 
deviation of 13 years, ranging from 20 to 87 years. Overall survival reached 31% 
with a median of 53 months. The tumor size ranged from 0.2 to 6.0 cm in diameter 
and was 1.9 cm on average.  
Due to tissue insufficiency, 27 TMA samples could not be evaluated. As a result, 
190 of 217 samples were validated, with 108 applicable cases for primary tumors, 
68 for lymph node metastases and 14 for distant metastases. Since many 
patients provided matching pairs of primary tumor and metastasis, 115 clinical 
cases were validated without regard to primary or secondary (metastasic) 
provenance of the tissue.  
Relating to the UICC TNM criteria, 6% of the samples (7/115) were assigned 
stage I, 5% (6/115) stage IIA, 4% (5/115) stage IIB, 0.9% (1/115) stage IIIA, 32% 
(37/115) stage IIIB, 48% (55/115) stage IV and in 3% (4/115) the stage was not 
identified. Stage IIIB and IV predominance corresponds with typically late clinical 
SI-NET manifestation. 
The samples were tested for the expression of neuroendocrine biomarkers via 
IHC. 97% of the samples (174/180) featured synaptophysin (13% of which were 
weak, 40% moderate, 48% strong), 87% (156/180) were positive for serotonin 
(21% of which were weak, 18% moderate, 61% strong) and in 78% (140/180) 
SSTR expression was identified (19% weak of which were, 16% moderate, 65% 
strong). 
3.2. AURKA signals determined by fluorescence in situ hybridization 
3.2.1. AURKA signal count 
Genetic alterations in SI-NETs were analyzed using FISH. A considerable part of 
24% of the analyzed cases presented amplified AURKA signals, defined as >72 
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signals per 30 cells and detected as red spots (versus green centromere signals). 
In contrast to a normal signal count of 2, cells with AURKA amplifications 
displayed signals ranging from 3 to 6. The maximum signal number of the 
examined 30-cell units was 92. Figure 14 compares AURKA signals visualized 
by FISH in cells of an amplified case (a) to regular cells without amplifications (b) 





Figure 14. AURKA signals (red) visualized by FISH, magnification 1000x. a) An amplified case, b) a case 




Amplifications were identified in 17% of the primary tumors, in 19% of the node 
metastases and in 14% of the distant metastases, calculated from 108 applicable 
cases for primary tumors, 68 for node metastases and 14 for distant metastases, 
as listed in Table 10. Figure 15 visualizes the distribution of amplifications subject 
to tumor progression. 
 
Table 10. Percentage of AURKA copy number variations determined by FISH. P: primary tumor, LN: 
lymph node metastasis, DM: distant metastasis, Any: clinical cases irrespective of the spreading progress. 
AURKA Applicable cases Copy number variations 
P 108 17% (18/108) 
LN 68 19% (13/68) 
DM 14 14% (2/14) 
Any 115 24% (27/115) 
 
 
Figure 15. AURKA copy number variations grouped into primary tumor and metastases. Primary tumor, 
blue; lymph node metastasis, yellow; distant metastasis, red. Clinical cases n = 115. 
 
An increased signal count can be based on different conditions: specific gene 
amplifications, polysomy or both at the same time, distinguishable by centromere 
signal and gene to centromere ratio (as described in 2.4.). The identified AURKA 
copy number gains were most frequently caused by polysomy (93%) with an 
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average centromere count of 77.3 (calculated from SRC signal counts due to 
inconsistent signal intensities of the centromere probe) and an average AURKA 
to centromere ratio of 1.02. However, a small amount (7%) of specific gene 
amplifications was detected. 
3.2.2. Comparison of AURKA copy number gains to the findings of Banck et al. 
The whole-exome study of Banck et al. included primary tumor sequencings of 
48 patients. Thereby, AURKA amplifications were demonstrated in 25% (12/48) 
of the investigated cases.[28] Related to this analysis, a more detailed insight 
into the frequency and coherence of AURKA alterations was sought by the use 
of FISH. 135 clinical cases with 217 provided samples of primary tumor and 
metastases were taken into account for statistical computing, considerably 
exceeding the number of cases of Banck et al. This allowed for a more accurate 
statement about firstly, the representativeness of the overall results and 
secondly, the allocation of amplified cells in primary tumor and lymph node or 
distant metastases, which has not been discriminated by Banck et al. The 
comparison of copy number gains detected by FISH and WES (aligned by 
AURKA’s chromosomal position) yielded similar rates in both collectives. 
3.2.3. Relationship between AURKA copy number gains and chromosome 18  
Statistical analysis of AURKA copy numbers compared to loss of chromosome 
18 as most frequent genetic alteration in SI-NETs identified a significant 
interdependency of increased AURKA signal counts and chromosome 18 loss in 
primary tumors (p = 0.028). The association of metastases and chromosome 18 
was also tested but did not achieve a significant result. 
3.2.4. Influence of AURKA copy number gains on tumor stage 
Another question to consider is how AURKA signal enhancement interrelates with 
tumor stages. Copy numbers were statistically tested for correlation with TNM 
criteria and with an internal cluster of UICC stages (encoded 1, 2 and 3). TNM 
criteria did not seem to be affected by AURKA amplifications, neither in primary 
tumors, nor in metastases. While AURKA signal counts tested separately in 
primary tumor, lymph node and distant metastases did not correlate with tumor 
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progress, they showed a definite tendency when tested in all clinical cases. In 
particular, advanced tumors presented with significantly increased copy numbers 
(p = 0.049 for UICC stages IIIA-IV and 0.020 for stages IIIB-IV) than tumors of 
lower stages (taken into account as a collective, as discussed in 2.1.). The 
distribution of amplified cases by UICC tumor stage is outlined in Table 11. Figure 
16 highlights the influence of AURKA amplifications on tumor progress in all 
clinical cases by comparing the rates of amplified to regular cases related to their 
corresponding UICC stage (clustered as encoded 3). 
 
Table 11. AURKA copy number gains separated into UICC stages.  
UICC stage Copy number gains 
I 0% (0/7) 
IIA 0% (0/6) 
IIB 20% (1/5) 
IIIA 0% (0/1) 
I - IIIA 5% (1/19) 
IIIB 17% (6/36) 





Figure 16. AURKA copy number gains matching UICC stage cluster. Clinical cases n = 111; p = 0.020. Not 
amplified, blue; amplified, green. 
 
3.2.5. Correlation of AURKA copy number gains and survival 
The impact of AURKA amplifications on overall survival was statistically tested 
with a Kaplan-Meier estimator for primary tumor and metastases both separately 
and combined. However, overall survival was not significantly affected by copy 
number gains. Figure 17 contrasts the Kaplan-Meier curves of amplified and 
regular cases taking into account all clinical cases without distinguishing primary 





Figure 17. Kaplan-Meier survival curves of clinical cases with and without AURKA amplifications. Clinical 
cases n = 67; p = 0.191. Not amplified, blue; amplified, green. 
 
3.3. AURKA protein expression analyzed by immunohistochemistry 
3.3.1. AURKA protein expression intensity 
The extent of AURKA expression was analyzed via IHC. Figure 18 shows an 
immunohistochemical staining of a representative SI-NET with high nuclear and 
moderate cytoplasmic AURKA expression. As indicated in Table 12, IHC verified 
moderate to strong nuclear expression in 56% of the primary tumors and 53% of 
the lymph node metastases. Distant metastases largely presented none or weak 
protein expression, with a minor part of moderate or high expression levels (21%). 
Cytoplasmic expression was mainly weak or not detectable. Moderate or strong 
protein expression was observed in 21% of the primary tumors, 12% of the lymph 




Figure 18. Immunohistochemical AURKA staining of a representative SI-NET tissue, magnification 400x. 
Moderate cytoplasmic expression (mid-brown), high nuclear expression (dark brown). 
 
Table 12. Nuclear (nc) and cytoplasmic (cp) AURKA protein expression. Percentage of none / weak and 
moderate / strong stainings in primary tumors (P), lymph node metastases (LN), distant metastases (DM) 
and in all clinical cases irrespective of spreading progress (Any). 
AURKA Applicable cases 0-1 staining      
(none / weak) 
2-3 staining 
(moderate / strong) 
P (nc) 108 44% (48/108) 56% (60/108) 
LN (nc) 68 47% (32/68) 53% (36/68) 
DM (nc) 14 79% (11/14) 21% (3/14) 
P (cp) 108 79% (85/108) 21% (23/108) 
LN (cp) 68 88% (60/68) 12% (8/68) 
DM (cp) 13 85% (11/13) 15% (2/13) 
Any 115 22% (25/115) 78% (90/115) 
 
Nuclear and cytoplasmic AURKA intensities are contrasted for primary tumors 




Figure 19. Nuclear (nc) and cytoplasmic (cp) AURKA protein expression in primary tumors (P), lymph node 
metastases (LN) and distant metastases (DM). None / weak expression, blue; moderate / strong expression, 
green. 
 
3.3.2. Correlation of nuclear and cytoplasmic AURKA expression 
The relationship between nuclear and cytoplasmic expression was statistically 
examined, including none, weak, moderate and strong stainings for primary 
tumors, lymph node metastases, distant metastases and all clinical cases 
(without regard to the spreading situation).  
Nuclear protein expression was proved to significantly interrelate with 
cytoplasmic protein expression in all clinical cases (p = 0.042). In other words, 
patients exhibiting high nuclear Aurora A levels were likely to present high 
cytoplasmic protein levels as well. Taking account of primary tumors, lymph node 
and distant metastases separately, however, did not show significant correlation 
of nuclear and cytoplasmic protein expression. Eventually, another tendency 
became evident: primary tumors and lymph node metastases are most frequently 
characterized by weak cytoplasmic and moderate nuclear expression (28% of the 
primary tumors and 24% of the lymph node metastases) while the major part 




3.3.3. Effect of AURKA copy number gains on protein expression 
In order to identify whether protein expression levels are related to increased 
AURKA signals, these variables were statistically analyzed. The test setting 
included matching pairs of FISH signals (amplified versus not amplified) on one 
hand and protein expression (non / weak vs. moderate / strong) on the other for 
primary tumors, lymph node metastases, distant metastases and all clinical cases 
combined. This analysis pointed out that there is no statistically significant 
influence of gene amplification on AURKA protein expression.  
3.3.4. Correlation of AURKA expression and tumor progress 
The association of Aurora kinase levels and tumor progress was tested in 
primary tumors and metastases in particular and in all clinical cases without 
regard to spreading. The testing correlated nuclear and cytoplasmic protein 
expression separately with TNM criteria and UICC stages. Considering UICC 
staging, significant results could not be detected. On the contrary, the test for 
TNM criteria disclosed a significantly high staining intensity in N stage tumors. 
This was verified for nuclear stainings of primary tumor samples (p = 0.044) and 
distant metastasis samples (p = 0.005) as well as for cytoplasmic stainings of 
distant metastases (p = 0.007). Correlations of protein expression and T or M 
stages, by contrast, could not be identified. 
3.4. SRC signals determined by fluorescence in situ hybridization 
3.4.1. SRC signal count 
The analysis of SRC proto-oncogene in SI-NETs via FISH revealed amplified 
signals (defined as >72 signals per 30 cells, detected as red spots versus green 
centromere signals) in 25% of the clinical cases. In contrast to the regular signal 
count of 2, SRC-amplified cells reached 3 to 6 signals. The examined 30-cell units 
featured 95 signal counts at the maximum. Figure 20 demonstrates the difference 
between SRC signals in an amplified sample (a) and a case with regular copy 





Figure 20. SRC signals (red) displayed by FISH, magnification 1000x. a) An amplified case, b) a case 




Increased signal counts were identified in 18% of the primary tumors, but more 
frequently in lymph node metastases (28%) and in distant metastases (29%), as 
listed in Table 13 with regard to the valid cases of each fraction. The proportion 
of amplifications derived from primary tumors, lymph node and distant 
metastases is portrayed in Figure 21. 
 
Table 13. SRC copy number variations determined by FISH. P: primary tumor, LN: lymph node metastasis, 
DM: distant metastasis, Any: clinical cases irrespective of spreading progress. 
SRC Applicable cases Copy number variations 
P 108 18% (19/108) 
LN 68 28% (19/68) 
DM 14 29% (4/14) 
Any 115 25% (29/115) 
 
 
Figure 21. SRC copy number variations in primary tumors and metastases. Primary tumor, blue; lymph node 
metastasis, yellow; distant metastasis, red. Clinical cases n = 115. 
 
Comparable to AURKA, SRC copy number gains largely (96%) resulted from 
polysomy of chromosome 20. The centromere mean count was 76.3 (calculated 
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from AURKA signals) with an average SRC to centromere ratio of 1.05. Only 4% 
of the increased signal counts could be derived from specific gene amplifications. 
3.4.2. Comparison of SRC copy number gains to the findings of Banck et al. 
In the sequencing study of Banck et al. SRC was amplified in 25% (12/48) of 
the examined cases and represented the most frequently amplified gene. Since 
the whole-exome analysis was limited to only 48 patients, SRC alterations were 
analyzed via FISH in a larger dimension with 135 cases and 217 single 
samples. This not only intended more accuracy but also to understand the 
distribution of amplifications among primary tumors and lymph node or distant 
metastases. The comparison of FISH analysis and WES results (aligned by 
SRC’s chromosomal position) yielded similar amplification rates in both 
collectives.  
3.4.3. Relationship between SRC copy number gains and chromosome 18 
Since chromosome 18 loss is the most prominent alteration to bear upon SI-
NETs, it is worthwhile finding out to which extent it correlates with SRC copy 
number gains. Statistical evaluation pointed out a significant association of 
these events (p = 0.027), at least for primary tumors.  
3.4.4. Influence of SRC copy number gains on tumor stage 
The impact of SRC copy numbers on tumor progression was tested for two 
variables: TNM criteria and UICC stage clusters (encoded 1 accounted for all 
stages separately, encoded 2 combined stages I-IIB, encoded 3 combined 
stages I-IIIA, as described in 2.1.). Regarding TNM criteria, there was no 
evident association with SRC signal gains, in none of the examined fractions 
(primary tumor, metastases and all clinical cases). While statistical analysis did 
not display a significant connection between SRC amplifications and UICC 
stages for lymph node or distant metastases, primary tumors and all clinical 
cases (without regard to the metastatic situation) were shown to be significantly 
influenced by SRC amplifications. In all UICC stage clusters SRC copy numbers 
were clearly correlated with tumor progress, which emphasizes that highly 
enhanced signals were particularly noticed in advanced primary tumors            
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(p = 0.021 for all stages separately; 0.004 for stages I-IIB versus IIIA, IIIB and 
IV; 0.032 for stages I-IIIA versus IIIB and IV) and in clinical cases in general      
(p = 0.004 for all stages separately; < 0.001 for stages I-IIB versus IIIA, IIIB and 
IV; 0.002 for stages I-IIIA versus IIIB and IV). Table 14 specifies the distribution 
of amplified cases by UICC tumor stage in primary tumors and all clinical cases. 
A comparison of SRC-amplified and regular samples for all clinical cases is 
provided for all stages separately in Figure 22 and for a UICC stage cluster 
(encoded 3) in Figure 23. 
 
Table 14. SRC copy number variations in primary tumors and in all clinical cases grouped by tumor stage. 
UICC stage Copy number variations 
in primary tumors 
Copy number variations 
in all clinical cases 
I 0% (0/7) 0% (0/7) 
IIA 0% (0/6) 0% (0/6) 
IIB 0% (0/5) 0% (0/5) 
IIIA 100% (1/1) 100% (1/1) 
I – IIIA 5% (1/19) 5% (1/19) 
IIIB 11% (4/36) 14% (5/36) 





Figure 22. SRC copy number variations matching single UICC stages. Not amplified, blue; amplified, green. 
Clinical cases n = 111, p = 0.004. 
 
 
Figure 23. SRC copy number variations matching clustered UICC stages. Not amplified, blue; amplified, 
green. Clinical cases n = 111, p = 0.002. 
 
3.4.5. Correlation of SRC copy number gains and survival 
Whether SRC copy number gains have an effect on overall survival was tested 
for primary tumors and metastases individually and for the clinical cases as a 
whole. There was no significant association in any of these categories, though. 
As demonstrated by the Kaplan-Meier curves in Figure 24, the survival functions 
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Figure 24. Overall survival represented by Kaplan-Meier curves with and without SRC amplifications. Not 
amplified, blue; amplified, green. Clinical cases n = 67, p = 0.717. 
 
3.5. SRC protein expression analyzed by immunohistochemistry 
3.5.1. SRC protein expression intensity  
SRC expression was examined via IHC and evaluated according to both 
Remmele score and dichotomic division. Figure 25 contrasts the high cytoplasmic 
SRC expression of a representative immunostained SI-NET sample with its 
negative nuclear expression. Protein levels were moderate or strong, as defined 
by Remmele score, in 93% of the primary tumors, 91% of the lymph node 
metastases and 86% of the distant metastases. Pursuant to dichotomic division, 
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moderate or strong expression was less frequent with only 49% in primary 
tumors, 32% in lymph node metastases and 29% in distant metastases, which 
implies that the major part of the samples featured rather moderate than strong 
protein expression. These results are summarized in Table 15.  
 
 
Figure 25. Immunohistochemical SRC staining of an exemplary SI-NET tissue, magnification 400x. High 
cytoplasmic, no nuclear expression. 
 
Table 15. SRC protein expression. Different staining intensities as a percentage of all applicable cases in 
primary tumors (P), lymph node metastases (LN), distant metastases (DM) and clinical cases irrespective 






















LN  68 9% (6/68) 91% (62/68) 68% (46/68) 32% (22/68) 
DM  14 14% (2/14) 86% (12/14) 71% (10/14) 29% (4/14) 








The differences of SRC expression in primary tumors and metastases are 
illustrated based on the Remmele IRS (Figure 26) and on dichotomic distribution 
(Figure 27). 
 
Figure 26. SRC protein expression based on the Remmele IRS in primary tumors (P), lymph node 




Figure 27. Dichotomic distribution of SRC protein levels in primary tumors (P), lymph node metastases (LN) 




3.5.2. Effect of SRC copy number gains on protein expression 
Statistical analysis of SRC signals compared to SRC expression was performed 
to figure out the relation of these variables. The testing included matching pairs 
of FISH signals (amplified versus not amplified) on one hand and protein 
expression (ascending staining intensity from 0 to 12) on the other for primary 
tumors, lymph node metastases, distant metastases and clinical cases 
characterized by any of these (without regard to spread category). 
Eventually, there is no evidence of significant correlation of amplified gene 
signals and protein expression for SRC. 
3.5.3. Correlation of SRC expression and tumor progress 
The impact of SRC expression on tumor progress was tested in primary tumors 
and metastases separately and in all clinical cases combined. For this purpose, 
SRC levels were correlated with TNM criteria and UICC stages (clustered as 
encoded 1, 2 and 3). Statistic results did not identify a connection between Src 
kinase expression and T or N stages in any constellation. Yet, primary tumors (p 
= 0.043) and clinical cases in general (subject to Remmele score evaluation, p = 
0.001) presented significantly high Src kinase levels in M stage. The comparison 
of SRC expression in distinct UICC stages yielded significantly high levels in 
lymph node samples of advanced stages (same p of 0.039 for all stages 
separately, for stages I-IIB opposite to IIIA, IIIB and IV and for stages I-IIIA 
opposite to IIIB and IV). However, this was not evident in primary tumors, distant 
metastases or clinical cases in general. 
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4. Discussion  
Neuroendocrine tissue scattered over several organs can give rise to 
heterogeneous tumors. In the small intestine, these neuroendocrine tumors are 
the leading malignancy. Since the majority is diagnosed when already spread, 
most patients do not benefit from surgery which is the only curative treatment so 
far. A potential target for innovative therapy could the molecular background of 
SI-NETs. 
A sequencing study conducted by Banck et al. in 2013 disclosed amplifications 
of two genes, located on chromosome 20: AURKA and SRC.[28] Prior to this, 
amplification and overexpression of both genes / proteins have been identified in 
many other cancer types. Elevated protein levels of the mitotic regulator AURKA 
is considered to cause irregular centrosome multiplication and spindle 
arrangement resulting in aneuploidy. SRC protein excess seems to support tumor 
invasion and dissemination stimulated by its downstream pathways.  
The present study focused on the identification of AURKA and SRC alterations 
in SI-NETs. While gene signals were registered by fluorescence in situ 
hybridization, protein expression was analyzed via immunohistochemistry. 135 
patients providing 217 tissue samples arranged as tissue microarrays were taken 
into account.  
Signal counts revealed AURKA gains in 24% and SRC gains in 25% of the 
investigated tumor samples. These results are consistent with the amplification 
rates provided by Banck et al.[28] FISH analysis yielded slightly higher copy 
number gains for both genes compared to the sequencing study. Considering the 
ratios of gene signal to calculated centromere signal, the attested copy number 
gains are largely characterized by chromosome 20 polysomy. Only a small 
fraction (7% for AURKA and 4% for SRC) could be attributed to specific gene 
amplifications. Toennies et al. verified chromosomal arm gains of 20q as frequent 
alteration (36%) in NETs of the midgut.[22] In this context, it is plausible that 
amplifications of larger chromosomal segments including the locations of AURKA 
and SRC (20q11.23 – 20q13.2) account for the identified signal increase.  
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A comparative analysis matched the FISH results against the NGS findings by 
Banck et al. for both genes. 25% of the cases evaluated as augmented by FISH 
featured corresponding gains of larger chromosomal regions which were rated 
as amplified by NGS. Apparently, the sequencing results are also based on 
polysomy. 
This investigation provided additional information about genetic properties of SI-
NET metastases. AURKA gains were distributed equally in metastases and 
primary tumors, whereas SRC gains most of all manifested in lymph node and 
distant metastases. 
Given the fact that primary tumors with loss of chromosome 18 displayed 
enhanced AURKA and SRC signals (p = 0.028 and 0.027, respectively), the 
question arises how these events relate to each other. In metastases, there was 
no evident relationship between these events but in early tumors, there was a 
significant correlation between loss of chromosome 18 and increased AURKA 
and SRC copy numbers. This is compliant with loss of chromosome 18 being 
considered an early event in tumor development.[25] Chromosome 18 loss 
correlating with AURKA / SRC increases due to chromosome 20 gains 
corresponds with several chromosomal interdependencies outlined by Francis et 
al.[29] A potential reason for this coexistence could be passenger chromosomal 
instability caused by loss of chromosome 18. 
Despite the lack of a significant effect on TNM criteria, AURKA and SRC copy 
number gains were significantly connected to advanced UICC stages. In 
particular, signals were higher in patients with advanced (UICC stage IIIB and IV) 
tumors (p = 0.020 for AURKA, p = 0.002 for SRC). This highlights the influence 
of AURKA and SRC copy number alterations on tumor progression. Assuming 
that chromosomal gains comprising AURKA and SRC are side effects of other 
driving events (such as chromosome 18 loss) they may play a minor role in 
primary tumor emergence but apparently promote invasion and dissemination. 
Overall survival of SI-NET patients did not noticeably depend on AURKA or SRC 
copy number gains, even though facilitated tumor spread clearly reduces the 
chance of survival. This can be explained by the late tumor manifestation and 
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diagnosis. Regardless of AURKA or SRC gene levels, SI-NETs are commonly 
identified in a metastatic state and are thus fatal. The long period of undetected 
tumor persistence makes it difficult to correlate underlying events and survival.  
In 78% of the considered cases, AURKA protein expression reached medium to 
high levels. There were generally higher levels in the nuclear than in the 
cytoplasmic compartment. At the same time, nuclear and cytoplasmic levels were 
significantly aligned in clinical cases, regardless of metastatic spread (p = 0.042). 
In other words, the higher the nuclear AURKA expression, the higher the 
cytoplasmic expression in the same patient. In both cell compartments, Aurora A 
expression was more intense in primary tumors than in metastases. Remarkably, 
distant metastases largely presented negative nuclei. Due to its predominance in 
primary tumors, nuclear Aurora A excess could be involved in the emergence of 
SI-NETs. This is plausible with Aurora’s regulatory function in mitosis but stands 
in contrast with the effect of AURKA copy number gains (considered to assist 
tumor spread).  
SRC expression was moderately high in 97% and very intensive in 62% of the 
examined cases. High levels, in particular, were more frequent in primary tumors 
than in metastases (49% versus 32% in lymph node and 29% in distant 
metastases, respectively). This is a surprising result because SRC copy number 
gains were demonstrated to determine advanced tumor stages with significant 
increase in metastases. Additionally, SRC proto-oncogene in other tumors turned 
out to control invasion and tumor spread and hence was more expected to assist 
tumor progress than tumor formation.[62] 
Catalytic activity was tested with antibodies targeting phosphorylation site Thr288 
for AURKA and Tyr527 for SRC. However, due to irregular staining, the results 
could not be evaluated. 
Amplified gene signals did not seem to have an influence on the expression level 
of encoded proteins, neither in the case of AURKA, nor in the case of SRC. This 
leads to the assumption that in the investigated SI-NETs, protein expression was 
not intensified by genetic variations but by other mechanisms. Since 
phosphorylation is a key regulator of both genes dysfunctional protein kinase 
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activity could lead to AURKA and SRC excess.[38,58] Even though several studies 
found coincidence of amplification and overexpression, high AURKA mRNA and 
protein expression were also found without copy number gains in solid 
cancers.[40,41] In particular, transcriptional activation, (post-)translational up-
regulation and reduced degradation were reported as a cause of 
overexpression.[43,85,86] In cells exposed to hypoxia such as tumor cells, HIF-1-
induced gene transcription lead to AURKA excess.[87] In EGFR-overexpressing 
cancer cell lines AURKA levels were shown to increase due to EGF-stimulation 
in various ways: nuclear EGF signaling acted as transcriptional activator and 
enhanced STAT5-mediated AURKA expression.[88] Additionally, EGF 
downstream protein mTOR raised translational efficiency of AURKA mRNA and 
specific splicing variants were associated with higher protein expression.[89] SRC 
protein levels in most cancers are mainly affected by (epi-)genetic alterations.[90] 
Increased SRC expression, however, was also ascribed to enhanced 
transcription in colon cancer cell lines and to deficient inhibitory phosphorylation 
in hepatocellular carcinoma.[60,91] EGF signaling not only affects AURKA but has 
also an impact on SRC protein levels, which was studied in human breast cancer 
cell lines. EGFR-member HER2 generated SRC up-regulation by activating 
downstream protein mTOR which intensified SRC translation.[92] Biscardi et al. 
identified a mutually potentiating interaction between SRC and HER1.[93] Since 
EGF-signaling plays an important role in both AURKA and SRC synthesis and 
amplifications of all three genes have been detected in SI-NETs protein 
interactions like these could explain overexpression independent of gene copy 
numbers in the analyzed tumor samples.  
This study provides an insight into molecular modifications in SI-NETs taking 
advantage of both target genes being located on chromosome 20. This 
compensated for the bias of single person evaluation. A similar effect was 
achieved by comparing immunohistochemistry stainings with the corresponding 
Definiens Tissue Studio extrapolation. The quantity of investigated patients and 
samples in this study was considerably higher than in the previous study by 
Banck et al. but especially for the newly acquired knowledge about the genetics 
and protein expression of distant metastases, the small number of samples 
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should be taken into account. Little sample supply due to a low incidence, 
however, is rated as general obstacle in exploring SI-NETs.[27] In order to provide 
a better understanding of this rare malignancy, a higher detection rate is 
indispensable. Diagnostics could be improved by polymerase chain reaction 
(PCR) based tumor cell analysis in serum, as introduced by Modlin et al. Due to 
higher sensitivity and specificity this method could replace current blood tests.[94] 
However, this would only confirm a suspected diagnosis and would not have an 
impact on patients without symptoms. Therefore, early SI-NET identification 
requires viable and inexpensive screening tools. 
In conclusion, AURKA signal gains were evident in 24% and SRC gains in 25% 
of the studied cases. Protein expression was considerably high in 78% for 
AURKA and 62% for SRC. In this way, previous findings were confirmed and 
supplemented by additional methods based on a larger case quantity. Increased 
gene signals (predominantly) turned out to be gains of major parts of 
chromosome 20, rather than specific gene amplifications. The discrepancy 
between the distribution patterns of primary tumors and metastases indicates a 
different influence of molecular and protein alterations on tumor emergence and 
dissemination. Protein overexpression has been pointed out as largely 
independent of gene copy number gains. Yet, both mechanisms seem to play a 
significant role in SI-NET development. 
Therefore, targeting these proteins with inhibitory agents in clinical studies could 
be profitable. Potential candidate agents include the AURKA inhibitors Alisertib 
or Danusertib and the SRC inhibitors Bosutinib or Dasatinib.  
Since AURKA and SRC are subject to similar regulation with complementary 
functions in tumorigenesis, the idea of dual protein inhibition came up. Ratushny 
et al. proved AURKA and SRC interactions in colorectal and ovarian cancer and 
achieved tumor cell death by simultaneously blocking both in vitro.[95] In 
consequence, synergetic effects of AURKA and SRC are interesting issues to be 




Neuroendocrine Tumors (NETs) are rare neoplasias of hormone-producing cells 
largely emerging from the gastroenteropancreatic system.[2] They represent the 
leading malignancy of the small intestine.[6] Due to their long asymptomatic 
progression SI-NETs are diagnosed late and most commonly in a metastatic 
stage. This limits the feasibility of radical surgery, the only curative therapy. Aside 
from local procedures to reduce tumor load somatostatin analogs and interferons 
are applied for symptomatic treatment. The development of specific 
immunotherapy requires an understanding of causal genetic modifications. Loss 
of chromosome 18 is an early event in cancer development and is thus 
considered the most important finding in gastrointestinal NETs.[21-25] Based on 
comparative genomic hybridization (CGH) analyses determining further 
chromosomal alterations, Banck et al. conducted a whole exome sequencing 
(WES) study using SI-NET samples of 48 patients. They confirmed several 
amplifications including chromosome 20 and associated genes that facilitate 
enhanced cell growth and reduced apoptosis, such as AURKA and SRC.[28]  
This thesis is focused on fluorescence in situ hybridization (FISH) analysis of 
these two genes and provides insight into their protein expression via 
immunohistochemistry. Comprising 217 SI-NET samples of 135 patients the 
study is fairly representative.  
Both genes were characterized by signal gains. AURKA gains were 
demonstrated in 24% and SRC gains in 25% of the studied cases in accordance 
with the results of Banck et al.[28] FISH attested slightly higher copy numbers 
compared to sequencing. For the most part these gains are ascribed to 
amplification of major chromosomal segments (polysomy) but a few samples also 
featured specific gene amplifications. Moreover, this analysis yielded a 
distribution pattern of copy number gains between primary tumor and 
metastases. A significant correlation between copy number gains in primary 
tumors and loss of chromosome 18 was demonstrated for AURKA and SRC (p-
value: 0.028 for AURKA and 0.027 for SRC). Since particularly high copy 
numbers were most notably detected in advanced tumors in UICC stages IIIB 
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and IV (p-value: 0.020 for AURKA and 0.002 for SRC) these alterations are most 
likely related to tumor invasion and dissemination. 
Protein analysis proved medium to high expression in 78% for AURKA and 97% 
for SRC. There were considerably higher levels of both proteins in primary tumors 
than in metastases. In contrast to their encoding genes, AURKA and SRC seem 
to be more involved in tumor emergence than in spreading.  
Even though increased expression at molecular and protein levels are both 
factors in SI-NET growth, there is no direct interrelation of these two. Instead, 
elevated protein levels potentially result from intensified transcription, 
translational up-regulation or reduced degradation.[43,85,86] In this context, the 
EGF-signaling pathway plays an important role in the control of both 
proteins.[88,89,92] 
AURKA / SRC have already been targeted by inhibitory agents such as AURKA 
inhibitors Alisertib or Danusertib and SRC inhibitors Bosutinib or Dasatinib in 
several cancer types. Future studies could therefore test these candidates for 




Neuroendokrine Tumoren (NETs) sind seltene, von hormonproduzierenden 
Zellen ausgehende Neoplasien, die zum größten Teil im 
gastroenteropankreatischen System entstehen.[2] Im Dünndarm stellen sie die 
häufigste maligne Entartung dar.[6] Aufgrund ihres langen asymptomatischen 
Verlaufs werden sie spät und meist im metastasierten Zustand diagnostiziert. 
Dies begrenzt die Möglichkeit einer chirurgischen Radikalresektion, der einzig 
kurativen Therapie. Abgesehen von lokalen Maßnahmen zur Reduktion der 
Tumorlast werden systemisch Somatostatin-Analoga und Interferone zur 
symptomatischen Behandlung eingesetzt. Voraussetzung für die Entwicklung 
spezifischer Immuntherapeutika ist das Verständnis zugrundeliegender 
genetischer Veränderungen. Der Verlust von Chromosom 18 ist ein frühes 
Ereignis während der Tumorentwicklung und gilt als wichtigste Erkenntnis im 
Rahmen gastrointestinaler NETs.[21-25] Ausgehend von Comparative genomic 
hybridization (CGH) Analysen, mit deren Hilfe weitere 
Chromosomenveränderungen festgestellt wurden, führten Banck et al. eine 
Whole exome sequencing (WES) Studie anhand SI-NETs von 48 Patienten 
durch. Dabei wurde unter anderem die Amplifikation von Chromosom 20 
untermauert, sowie Amplifikationen assoziierter Gene, die vermehrtes Wachstum 
oder verminderte Apoptose begünstigen, wie beispielsweise AURKA und 
SRC.[28] 
Die vorliegende Arbeit konzentriert sich auf die Analyse dieser zwei Gene mittels 
Fluoreszenz in situ Hybridisierung (FISH) sowie der Proteinprodukte anhand 
Immunhistochemie. Diese Untersuchung umfasst 217 SI-NET Proben von 135 
Patienten und ist verhältnismäßig repräsentativ. 
Beide Gene wiesen vermehrte Signale auf. AURKA war in 24% und SRC in 25% 
der Fälle vervielfältigt, was mit den Ergebnissen von Banck et al. 
übereinstimmt.[28] Mittels FISH wurde im Vergleich zur Sequenzierung jeweils 
eine geringfügig höhere Anzahl an Genkopien nachgewiesen.  Zum größten Teil 
handelt es sich hierbei um die Vervielfältigung größerer Chromosomenabschnitte 
(Polysomie), aber einzelne Fälle zeigten auch Amplifikationen spezifischer 
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Gensignale. Darüber hinaus lieferte diese Untersuchung ein Verteilungsmuster 
der vermehrten Gensignale zwischen Primärtumoren und Metastasen. Eine 
Korrelation zwischen erhöhten Genkopien und dem Verlust von Chromosom 18 
wurde für AURKA und SRC festgestellt (p-Wert: 0,028 für AURKA und 0,027 für 
SRC). Da erhöhte Gensignale vor allem in weit fortgeschrittenen Tumoren der 
UICC Stadien IIIB und IV (p-Wert: 0,020 für AURKA und 0,002 für SRC) vorlagen, 
ist ein Zusammenhang mit Tumorinvasion und Metastasierung wahrscheinlich.  
Auf Proteinebene zeigte sich in 78% der Fälle für AURKA und in 97% für SRC 
eine moderate bis starke Expression. Primärtumoren waren durch ein deutlich 
höheres Expressionsniveau beider Proteine gekennzeichnet als Metastasen. Im 
Gegensatz zu den kodierenden Genen scheinen AURKA und SRC eher an der 
Tumorentstehung als an der Metastasierung beteiligt zu sein. 
Obwohl eine verstärkte Expression sowohl auf molekularer als auch auf 
Proteinebene Einfluss auf die SI-NET Entwicklung hat, gibt es in diesem Fall 
keine direkte Wechselwirkung. Vielmehr könnte die erhöhte Proteinexpression 
eine Folge von verstärkter Transkription, Hochregulierung der Translation oder 
vermindertem Abbau sein.[43,85,86] Der EGF-Signalweg spielt bei der Regulierung 
beider Proteine eine wichtige Rolle.[88,89,92]  
Bei einigen Krebsarten wurden die AURKA Inhibitoren Alisertib oder Danusertib 
und SRC Inhibitoren Bosutinib oder Dasatinib bereits zur AURKA / SRC 
Antagonisierung eingesetzt. Zukünftige Studien könnten daher diese Substanzen 
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